Joshua Rhett to Cell Line, Tumor
This is a "connection" page, showing publications Joshua Rhett has written about Cell Line, Tumor.
Connection Strength
0.059
-
Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants. Cell Rep. 2022 02 08; 38(6):110322.
Score: 0.037
-
Targeting connexin 43 with a-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1. BMC Cancer. 2015 Apr 03; 15:296.
Score: 0.023